BRK-B vs MET
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
MET presents a conflicted profile with a stable Piotroski F-Score of 4/9 and a current price ($78.28) trading at a significant premium to both its Graham Number ($67.77) and Intrinsic Value ($32.97). While the company exhibits strong top-line revenue growth (27.6% YoY) and an attractive forward P/E of 7.15, these are offset by a concerning decline in YoY earnings growth (-34.2%). The stock is currently in a technical transition, showing strong short-term momentum (+14.7% in 1 month) despite a bearish overall technical trend score. The valuation suggests the market is pricing in a recovery in earnings that has not yet materialized in the hard data.
Compare Another Pair
Related Comparisons
BRK-B vs MET: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and MetLife, Inc. (MET) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.